All companies
Visit website
CytexOrtho
OperatingCytex Therapeutics, Inc.
Healthcare · Founded 2006
One biodegradable implant, full restoration
Post-money valuation ⓘ
$18.7M
As of Jan 2023 · from CytexOrtho Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$304,029
Across 1 round since 2022
Latest share price
$2.00
CytexOrtho Common Stock 1 offering price
Financials
FY2020–FY2024 · from SEC filings · hover any figure for its source$1.8M
$40K
2020
$1.8M
−$23K
2021
$1.1M
−$622K
2022
$1.3M
−$1.2M
2023
$1.4M
−$1.1M
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
FY2022
FY2023
FY2024
Income statement
Revenue
$1,845,230
$1,836,602
$1,052,219
$1,284,927
$1,366,195
Cost of goods sold
$1,288,308
$1,263,476
$731,921
$858,498
$985,982
Gross margin
30%
31%
30%
33%
28%
Net income
$40,442
-$22,653
-$621,726
-$1,214,922
-$1,069,206
Taxes paid
$0
$0
$14,219
-$10,845
-$2,186
Balance sheet
Cash
$267,208
$489,299
$474,993
$170,770
$249,960
Accounts receivable
$197,422
$66,611
$47,914
$57,591
$45,658
Total assets
$480,707
$626,138
$719,644
$385,279
$536,278
Short-term debt
$233,574
$144,543
$193,580
$192,787
$231,628
Long-term debt
$0
$250,000
$490,492
$575,135
$957,036
Total liabilities
$233,574
$394,543
$684,072
$767,922
$1,188,664
Other
Headcount
—
8
9
8
8
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$18.7M
post-money
CytexOrtho Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $304K / $1.1MInvestors 258Post-money $18.7M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 3 of 4 annual reports (FY2022–FY2025)
258 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001943908Share price $2.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.